Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide

BACKGROUND: Thalidomide has potent anti-inflammatory and anti-angiogenic properties. It was evaluated in combination with chemotherapy in two randomised placebo-controlled trials in patients with small cell lung cancer (SCLC, n=724) and advanced non-small cell lung cancer (NSCLC, n=722). Neither stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, R J, Tin, A W, Brown, N J, Jitlal, M, Lee, S M, Woll, P J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304418/
https://www.ncbi.nlm.nih.gov/pubmed/22353811
http://dx.doi.org/10.1038/bjc.2012.50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304418/
https://www.ncbi.nlm.nih.gov/pubmed/22353811
http://dx.doi.org/10.1038/bjc.2012.50

Ejemplares similares